GlassScriptPhysician profile
Nicholas Ray Spear
NPI 1144985128
$611.97
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $594 · 2024: $17.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.03 |
| Education | $185.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $127.65 | 2023 | Alunbrig |
| Incyte Corporation | $110.67 | 2023 | Jakafi |
| Seagen INC. | $34.47 | 2023 | Adcetris |
| Beigene USA, INC. | $26.00 | 2023 | Brukinsa |
| Celgene Corporation | $25.74 | 2023 | Reblozyl |
| Octapharma USA, INC. | $24.89 | 2023 | Panzyga |
| Janssen Biotech, INC. | $24.27 | 2023 | |
| Adaptive Biotechnologies Corporation | $23.27 | 2023 | Clonoseq |
| Puma Biotechnology, INC. | $22.83 | 2023 | |
| Stemline Therapeutics INC. | $22.58 | 2023 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $22.48 | 2023 | Imfinzi |
| Sobi, INC | $22.43 | 2023 | |
| Tolmar, INC. | $18.53 | 2023 | |
| Pfizer INC. | $17.64 | 2024 | |
| Daiichi Sankyo INC. | $15.86 | 2023 | Injectafer |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.31 | 2023 | Keytruda, Lynparza |
| Lilly USA, LLC | $15.11 | 2023 | Retevmo, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $14.88 | 2023 | |
| Sumitomo Pharma America, INC. | $13.73 | 2023 | Orgovyx |
| Heron Therapeutics, INC. | $13.63 | 2023 | Sustol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Spear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.